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Background: Wider clinical applications of 9p status in clear cell renal cell carcinoma (ccRCC) are limited owing to the lack of
validation and consensus for interphase fluorescent in situ hybridisation (I-FISH) scoring technique. The aim of this study was to
analytically validate the applicability of I-FISH in assessing 9p deletion in ccRCC and to clinically assess its long-term prognostic
impact following surgical excision of ccRCC.
Methods: Tissue microarrays were constructed from 108 renal cell carcinoma (RCC) tumour paraffin blocks. Interphase fluorescent
in situ hybridisation analysis was undertaken based on preset criteria by two independent observers to assess interobserver
variability. 9p status in ccRCC tumours was determined and correlated to clinicopathological variables, recurrence-free survival
and disease-specific survival.
Results: There were 80 ccRCCs with valid 9p scoring and a median follow-up of 95 months. Kappa statistic for interobserver
variability was 0.71 (good agreement). 9p deletion was detected in 44% of ccRCCs. 9p loss was associated with higher stage, larger
tumours, necrosis, microvascular and renal vein invasion, and higher SSIGN (stage, size, grade and necrosis) score. Patients with
9p-deleted ccRCC were at a higher risk of recurrence (P¼ 0.008) and RCC-specific mortality (P¼ 0.001). On multivariate analysis,
9p deletion was an independent predictor of recurrence (hazard ratio 4.323; P¼ 0.021) and RCC-specific mortality (hazard ratio
4.603; P¼ 0.007). The predictive accuracy of SSIGN score improved from 87.7% to 93.1% by integrating 9p status to the model
(P¼ 0.001).
Conclusions: Loss of 9p is associated with aggressive ccRCC and worse prognosis in patients following surgery. Our findings
independently confirm the findings of previous reports relying on I-FISH to detect 9p (CDKN2A) deletion.
The predictive role of the detection of chromosomal and gene copy
number variation (CNV) in renal cell carcinoma (RCC) has been
explored in several studies (Gunawan et al, 2001; Klatte et al, 2009).
Deletion of the short arm of chromosome 9 (9p) has been
confirmed, in many studies, to be one of the most frequent non-
random chromosomal CNVs in clear cell RCC (ccRCC) (Strefford
et al, 2005; Matsuda et al, 2008; Beroukhim et al, 2009; Dalgliesh
et al, 2010). Moreover, accumulating evidence from other cancers
indicates frequent 9p deletions to be seen in high-grade invasive and
aggressive cancers (Sidransky, 1995; Okami et al, 1997; Ellsworth
et al, 2008). Potential genes on chromosome 9p have been
implicated in ccRCC progression. The cyclin-dependent kinase
inhibitor (CDKN2A) gene is a tumour suppressor gene, located on
9p21, encodes two proteins (p16INK4 and p14ARF) that regulate
two critical cell cycle regulatory pathways: the p53 pathway and the
Rb pathway (Harris and Levine, 2005). Thus, the inactivation of
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CDKN2A gene via 9p21 deletion, leading to low expression of these
regulatory proteins, may be an important biomarker of cancer
aggressiveness (Kawada et al, 2001a; Ikuerowo et al, 2007). Also, the
low level of expression of carbonic anhydrase IX (CAIX) gene
located on locus 9p13 has been associated with shorter survival and
poor response in patients on immunotherapy for metastatic lesions
(Bui et al, 2003; Atkins et al, 2005; Sandlund et al, 2007; Patard et al,
2008). Thus, established loss of 9p in RCC could act as a marker of
tumour aggressiveness and could be responsible for progression
(Cairns et al, 1995; Kinoshita et al, 1995; Schullerus et al, 1997;
Junker et al, 2003; Klatte et al, 2009; Dagher et al, 2013).
Recently, two studies, using interphase fluorescence in situ
hybridisation (I-FISH) as the main detection technique, have
concluded that loss of 9p in ccRCC was an independent prognostic
factor besides other known pathological parameters (Brunelli et al,
2008; La Rochelle et al, 2010). Although the findings from these
studies were promising, they were both of limited clinical
applicability owing to lack of standardisation of I-FISH scoring,
lack of reporting on degree of interobserver variability and a
modest follow-up period. La Rochelle et al (2010) performed
I-FISH analysis on a cohort of 316 patients but the cut-off level for
9p deletion was arbitrary, which could have possibly resulted in
underestimation of CNVs.
As I-FISH can be performed on both fresh and archived
formalin-fixed paraffin-embedded (FFPE) tumour tissue, it has
been used widely on tissue microarrays (TMAs)that allow the
assessment of many tumours in one experiment, in comparison to
conventional cytogenetics that can only be performed on
individual cases from fresh tissue after culture. Also, I-FISH
assesses CNVs at a cellular level, in contrast to other techniques,
such as array comparative genomic hybridisation and microsa-
tellite analysis based on mass DNA extraction, which can conceal
CNVs and intratumour cellular genetic complexity and hetero-
geneity (Bayani and Squire, 2007).
On the other hand, standardisation of I-FISH scoring
techniques and reaching a consensus on how to determine the
threshold level are required before the technique can be applied in
translational renal oncology (Junker et al, 2013). This is due to the
fact that the scoring process can be influenced by fading signals,
sectioning of paraffin blocks and quality of tissue preserved, which
can result in interobserver disagreement.
Our study aims to assess the prognostic effect of 9p deletion in
ccRCC subtype. We hypothesised that patients with 9p-deleted
ccRCC tumours detected by I-FISH do not carry a worse prognosis
(H0). A set of objectives was identified to test our hypothesis: (a) to
analytically validate I-FISH scoring technique for assessing 9p status
in renal cancer, (b) to assess the degree of interobserver variability in
scoring 9p status, (c) to assess the correlation between 9p status and
other established clinicopathological prognostic variables and finally,
(d) to assess the impact of 9p loss in ccRCC tumours on recurrence-
free survival (RFS) and disease-specific survival (DSS) in a cohort of
patients with at least 8 years of follow-up.
MATERIALS AND METHODS
Identification of cohort. The urology department database was
searched for consecutive patients who underwent radical nephrect-
omy for RCC between January 2001 and December 2005 without
any exclusion criteria. The period was chosen to allow a sufficient
follow-up period of at least 8 years for each patient. Ethical
approval (Ref. 12/ES/0083) was obtained from the Tayside
Research and Ethics committee. A single pathologist (SF) with
special interest in renal cancer, blinded to clinical outcomes,
reviewed all the samples using pathology number identifier for
each patient.
Tissue microarrays. Haematoxylin and eosin (H&E) slides from
all the archived FFPE blocks were reviewed for representative areas
in RCC tumours. Tissue microarrays were constructed as described
in previous publication from our institution (Hadad et al, 2009).
Hundred and twenty six FFPE blocks from 108 tumours, identified
from the pathology department archives, were used to construct
four tumour TMAs. Sixteen tumours were represented by two
blocks and one tumour was represented by three blocks. These
extra blocks served as internal control to assess the effect of tumour
heterogeneity without the knowledge of the scoring observer. One
TMA of normal renal tissue from same cases was prepared to serve
as a negative control.
Briefly the technique is described here. Tissue microarrays were
constructed using Beecher arraying instrument (Beecher Instruments
Inc., Sun Prairie, WI, USA) with the help of TMA Designer 2 software
(ALPHELYS, Plaisir, France). The pathologist identified and marked,
with a circle on the H&E slide, areas containing only tumour for
coring, and avoiding areas of necrosis or normal tissue, before marking
the same tumour region on the corresponding formalin-fixed paraffin
block. Tissue cores with a diameter of 0.6 mm were punched from the
marked tumour regions on paraffin blocks. Cores were then deposited
into a master paraffin block and placed 1.2mm apart from the
neighbouring core on the x and y axes. Sections from the resulting
master paraffin block measuring 4mm in thickness were then
transferred onto glass slides to form a TMA. Each TMA contained a
maximum of 240 tumour cores plus two spleen control cores for
orientation. Each case was represented at least with six tumour cores.
Interphase fluorescent in situ hybridisation. Interphase fluor-
escent in situ hybridisation analysis was performed using the Vysis
locus-specific identifier (LSI) CDKN2A spectrum red (R)/(CEP 9)
spectrum green (G) probes (Abbott Molecular, Des Plaines, IL,
USA). The CDKN2A probe spans B222 kb of the 9p21 region
across several genes, including p16 (INK4A), p14 (ARF) and p15
(INK4B). CEP 9 is a centromeric probe that hybridises to a-satellite
sequences specific to chromosome 9 (9p11-q11).
Tissue microarray slides were baked for 60min at 60 1C in a dry
incubator and then processed in automated Vysis VP-2000
processor (Abbott Molecular) to deparaffinise the slides. The slides
were submersed in Xylene basin for 10min twice, then alcohol
100% basin for 5min twice before they were left to dry for 2min.
The slides were left in 0.2 N HCL basin for 20min before they were
rinsed in a water chamber for 3min. The slides were then washed
twice in 2 SSC basin each for 3min before they were removed
from VP-2000. Next, slides were put through sodium thiocyanate
(NaSCN) pretreatment reagent (Abbott Molecular) at 80 1C for
30min followed by protease solution (0.5mgml-1 0.01 N HCl)
(Abbott Molecular) at 37 1C for 50min. Slides were then put
through three sequential 2-min washes with 2 SSC and then
dehydrated for 2min each in graded ethanol solutions (70%, 85%
and 100%). Once dried, slides were placed in 70% formamide/2
SSC at 70 1C in a water bath for 5min, removed, put through a
further graded ethanol series (70%, 85% and 100%) for 1min each
and then allowed to dry.
For each slide, a probe mix was made up by combining 4ml
CDKN2A/CEP 9 probe, 21ml LSI/WCP Vysis hybridisation buffer
(Abbott Molecular) and 6ml dH2O in a 200ml Eppendorf tube. The
probe was mixed and denatured by placing the mix in a 70 1C water
bath for 5min. The mix (31ml) was then drawn up and pipetted onto
a 22 50mm coverslip. The dried slide was then lowered onto the
coverslip, ensuring that the probe mix was evenly distributed and that
no air bubbles were present. Slides were then sealed around the edges
with rubber cement Fixogum (Kreatech Diagnostics, Leica Micro-
systems, Milton Keynes, UK) and placed overnight (B12h) in a
humidified hybridisation chamber in a 37 1C incubator.
The following day, cover slips were peeled off. Slides were placed
in a hot wash (0.4 SSC/0.3% NP-40 (Vysis, Abbott Molecular))
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for 2min at 70 1C in a water bath and then in a room temperature
wash (2 SSC/0.1% NP-40) for a further 2min. Once dried, slides
were counterstained with 25ml DAPI Antifade (Abbott Molecular),
mounted onto a fresh coverslip and edges sealed with nail varnish.
Slides were stored in covered slide trays at 4 1C before and after scoring.
Interphase fluorescent in situ hybridisation interpretation.
Slides were viewed under an Olympus B 60 fluorescent
microscope (Olympus Corporation, Tokyo, Japan) with filters for
red spectrum, green spectrum and DAPI nuclear counterstain.
Scoring was undertaken by two independent observers (IEM and
JF) blinded to clinical or pathological outcomes. Each observer
counted the number of red and green signals in each nucleus using
preset criteria. A minimum of 30 intact non-overlapping cells per
core, a minimum of three cores per block and a minimum of 100–
200 nuclei with good signals per case were required for valid
scoring. If these criteria were not met, the scoring was considered
invalid. The interpretation of nuclei probe patterns was as follows:
2G2R was interpreted as normal, abnormal patterns included:
2G1R as loss of heterozygosity (LOH), 2G0R as homozygous
deletion and 1G1R as monosomy of chromosome 9. Other nuclei
patterns were labelled as ‘unclassified’.
The threshold for 9p deletion was determined by calculating the
mean percentage (%) of abnormal nuclei from cores on the TMA
of normal renal tissue plus four times the standard deviation as
previously described in the literature (Cossu-Rocca et al, 2006;
Brunelli et al, 2008). This translated to the following cut-off values
for 9p deletion: 18% for LOH and homozygous loss of 9p (2G1R/
2G0R), 37% for monosomy (1G1R), and 42% for all abnormal
patterns. A tumour was scored 9p deleted if the number of cores
with 9p deletion was higher than those with normal 9p status.
When the number of cores with and without 9p deletion was equal,
we relied on the mean percentage of 9p-deleted nuclei in all cores
to decide on deletion. Each observer independently determined
the deletion status on the basis of the above criteria (Figure 1).
In tumours represented with cores from more than one block,
they were considered deleted if the cores from one of the
blocks were scored deleted. The level of interobserver agreement
was assessed and any scoring disagreement was settled by
consensus.
Clinicopathological data. The clinicopathological and follow-up
data up to December 2013 for each patient were retrieved
retrospectively using a unique 10-digit Community Health Index
number and recorded on a predesigned electronic database sheet
by an independent researcher (JB), blinded to chromosome 9p
status. The following Tayside Health Board electronic resources
were searched to retrieve and were cross-validated for clinical and
follow-up information:
Hospital records: namely, clinical portal, ICE and In-House
Surgical Information System Web and Technology (in-site). These
databases represent single, secure, electronic, patient-record
sources.
Multidisciplinary board meeting records: all renal cancer cases
were discussed in weekly uro-oncology meeting during the study
period. The records for each patient were available as an MS Word
file under the heading ‘kidney’.
Data including patients’ gender, age at diagnosis and pre-
operative staging were retrieved. Pathology slides review and
reports were used to identify tumour stage based on 2009 TNM
staging (Sobin et al, 2009), tumour size, Fuhrman grade, tumour
necrosis, pelvicalyceal invasion, renal sinus invasion, microvascular
invasion and sarcomatoid features. Each case was assigned a Mayo
Clinic SSIGN(stage, size, grade and necrosis) score and stratified
into five subcategories (SSIGN score subcategories 0–2, 3–4, 5–6,
7–9 and X10, respectively) (Frank et al, 2002). Stage, size, grade
and necrosis score has been externally validated in previous studies
and established as a reliable prognostic model (Ficarra et al, 2006;
Fujii et al, 2008; Ficarra et al, 2009).
Follow-up was calculated from the time of surgery to the last
date of assessment or the date of death. Cause of death was
determined on the basis of death certificates and correspondence
between clinicians and patients’ general practitioners. All patients
were followed up on the basis of a standardised departmental
protocol based on tumour stage and grade. Death from renal
cancer was defined as disease-related mortality. Recurrence was
diagnosed if RCC metastasis or renal bed recurrence was detected
on cross-sectional imaging and confirmed in a multidisciplinary
team meeting record.
Statistical analysis. The number of cores and nuclei scored by
each observer was compared. The level of interobserver agreement
upon validity of scoring and deletion status per represented block
of tumour was assessed using Kappa statistical analysis.
The clinicopathological data were compared based on 9p status.
Proportions between categorical variables were compared using
Fisher exact and Pearson chi-square tests, as appropriate. The
survival time was summarised using median and interquartile
range (IQR). Other continuous variables were summarised as
means (s.d.), and compared using Student’s t-tests or Wilcoxon
rank test, as appropriate. The Kaplan–Meier method was used to
estimate RFS and DSS based on 9p status and other variables. The
log-rank test was used to compare the survival differences between
the groups.
A univariate Cox proportional hazard model was used to assess
the correlation between prognostic variables and recurrence, and
RCC-specific mortality. Multivariate analysis was performed for
DSS and RFS after excluding the insignificant variables on
univariate analysis. For DSS, two models were generated: one
included all the significant variables except SSIGN score, and the
other was fit with SSIGN score and all the other significant
variables not incorporated in the SSIGN algorithm. A backward
selection manner with the likelihood ratio criterion (for entry and
removal: Pp0.05 and P40.1, respectively) and rank of
elimination was used to identify the most significant variables to
be entered in a final model for RFS and two final prognostic
models for DSS. The predictive accuracy of prognostic models was
assessed by employing Concordance index (C-index). Statistical
analysis was performed using IBM SPSS version 21 (IBM
Corporation), with all tests being two-tailed and Po0.05
considered statistically significant.
RESULTS
There were 89 (82.4%) patients with ccRCC tumours, 13 (12%) with
papillary RCCs (pRCCs), 5 (4.6%) with chromophobe RCCs and 1
(1%) with collecting duct carcinoma. Ten tumours (nine ccRCCs
and one pRCC) could not be scored due to poor signal, or core loss,
or excess connective tissue, or tissue damage or necrosis.
Interobserver agreement of FISH scoring. Out of 756 tumour
cores, observer 1 scored 534 (70%) compared with 517 (68%) cores
by observer 2 on the basis of the preset criteria. The mean number
of cores per tumour block scored by each observer was comparable
(4.6 out of 6 vs 4.45 out of 6; P¼ 0.055). Also, the mean number of
nuclei per tumour block scored by each observer was comparable
(mean 151.4 vs 147.8; P¼ 0.645). Both observers agreed upon 9p
status or invalid scoring in 105 out of 126 (83%) tumour blocks with
a kappa statistic for interobserver agreement of 0.71 (good agreement;
95% CI 0.60–0.82; Po0.0001). Deletion was detected and agreed
upon in 37 tumour blocks with LOH being the predominant deletion
pattern (n¼ 21), followed by monosomy (n¼ 13) and homozygous
deletion (n¼ 3). Both observers agreed on a no-deletion status and
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invalid scoring in 58 and 10 blocks, respectively. Two out of the 17
tumours represented by more than one block showed variation for
9p status between the blocks.
The pooled mean percentage of abnormal nuclei, in the agreed
upon 9p-deleted tumour blocks, was 52.5% (range 35–97%) and
54% (37–98%) for observer 1 and observer 2, respectively
(P¼ 0.782). Whereas in the non-9p-deleted tumour blocks, the
pooled mean percentage of abnormal nuclei was 23% (range
7–42%) and 25% (6–47%) for observer 1 and observer 2,
respectively (P¼ 0.4). In the agreed-upon blocks, the detection of
9p deletion increased with the total number of cores scored. 9p
deletion was observed in 25% of blocks where three cores were
scored compared with almost 50% of blocks where the six
representative cores were scored (Figure 2).
Both observers disagreed on scoring 21 tumour blocks. The
majority of discordance was due to the invalid scoring by one
observer (n¼ 10). In the rest of discordant cases (n¼ 11), there
was a significant difference in the percentage of abnormal nuclei
between both observers, which required a slide review to reach a
consensus.
We scored 10 whole-tissue sections from tumours on which
both observers agreed on 9p status. The five non-deleted tumours
showed abnormal nuclei ranging between 11 and 23% (mean 19%)
in whole-tissue section compared with 15 and 30% (mean 20.3%)
in the representative cores. On the other hand, the five tumours
with 9p deletion showed a range of abnormal nuclei between 66
and 93% (mean 78%) on whole sections compared with a range
between 53 and 97% (mean 71%) in the corresponding cores. The
overall concordance between whole sections and tissue array cores
was 100%.
Clinicopathological parameters. There were 98 out of 108
tumours with valid 9p deletion status and complete pathological
and follow-up data for analysis. Only patients with ccRCC tumours
(n¼ 80), with mean age of 62.96 years (s.d.±11.64) and male to
female ratio of 5 : 3, were included in the analysis.
Table 1 summarises the clinicopathological parameters based on
chromosome 9p status. 9p deletion was observed in 44% of the
tumours (35 out of 80). The mean age of the 9p-deleted group was
65.92 (s.d.±10.7) years compared with 60.4 (s.d.±11.92) years in
the non-9p-deleted group (P¼ 0.043).
The mean size of 9p-deleted tumours was 7.7 cm (s.d.±3.42) vs
5.6 cm (s.d.±2.54) for non-9p-deleted ones (P¼ 0.002). Also,
9p loss was significantly associated with higher pathological
T-stage (P¼ 0.021), presence of tumour necrosis (P¼ 0.019),
9p deletion threshold = mean (%) abnormal nuclei from cores of normal renal tissue+4SD*
Forms of 9p deletion
LOH: 2G1R
Monosomy: 1G1R
Homozygous: 1G/0R - 2G0R
Two independent observers
A minimum of three cores of renal tumour
A minimum of 30 intact non-overlapping cells per core
A minimum of 100 nuclei with good signals per case
Yes No Invalid scoring
Deletion status in each core based on predetermined threshold (%)
The number of 9p deleted cores vs the number of non-9p deleted cores
9p deleted>non-9p deleted 9p deleted=non-9p deleted 9p deleted<non-9p deleted
Pooled mean percentage of 9p-deleted nuclei in all cores scored
Higher than threshold Lower than threshold
9p-deleted tumour Non-9p-deleted tumour
*Standard deviation
Figure 1. Algorithm for interphase FISH scoring of 9p deletion using the Vysis locus-specific identifier (LSI) CDKN2A spectrum red
(R)/ chromosome 9 centromeric-enumeration probe (CEP9) spectrum green (G).
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microvascular invasion (P¼ 0.032) and renal vein invasion
(P¼ 0.046) compared with non-9p-deleted tumours.
Twelve patients (15%) had metastatic disease at diagnosis. Two
had regional lymph node metastasis, eight patients had distant
metastasis involving typical sites: adrenals, lungs and liver. One
patient had metastasis to an unusual site, the bladder wall that was
confirmed on resection pathology. Only one patient had both
regional lymph node and distant liver metastases. In this cohort, 9p
status was not associated with a higher risk of metastasis
(P¼ 0.156).
In total, there were 30, 8, 17, 16 and 9 patients with 0–2, 3–4,
5–6, 7–9 and X10 SSIGN scores, respectively. 9p-deleted tumours
were associated with higher SSIGN scores (P¼ 0.033).
Survival analysis. The median follow-up for patients with ccRCC
was 95 months (IQR 40.5–115.5 months). In total, 40 patients
(50%) died at the end of the follow-up period, 20 patients (25%)
died from advanced renal cancer, whereas 20 patients died from
non-RCC-related causes. Nine cases died from a second advanced
malignancy including lung (n¼ 2), breast (n¼ 3), pancreatic
(n¼ 1), colorectal (n¼ 2) and melanoma (n¼ 1) with no sign of
renal cancer recurrence. One died from sepsis and acute kidney
injury on day 8 post nephrectomy. Eleven patients died from other
causes including sepsis, cerebrovascular accident, auto-immune
hepatitis and severe pancreatitis from gall stones.
The median DSS for tumours with 9p loss was 87 months (IQR
31–112 months) compared with 97 months in non-9p-deleted ones
(IQR 53–120 months; P¼ 0.291). At 1, 5 and 10 years of follow-up,
15%, 39% and 55% of patients with 9p loss died from ccRCC,
respectively, as compared with 0%, 5% and 11% in patients
with normal 9p (Po0.001) (Figure 3a). Also, tumour size
X5 cm, pathological T3 and T4 stages, Fuhrman grades 3 and 4,
presence of metastasis (NþMþ ), tumour necrosis, microvascular
invasion, renal vein invasion, pelvicalyceal invasion, renal sinus
invasion and SSIGN scores were all variables associated signifi-
cantly with cancer-specific mortality on univariate analysis
(Table 2).
There were 19 patients with clinically localised small renal
masses (SRMs) (cT1a) in this cohort (o4 cm) with a mean size of
2.9 cm (s.d.±0.66 cm) with a median follow-up of 107 months
(IQR 42–128 months). Two out of the five patients (40%) with
9p-deleted SRMs died from advanced renal cancer. Those two
SRMs were found to be invading the renal sinus and perinephric
fat and were staged as pT3a. On the other hand, none of the
patients with normal 9p status SRMs had a ccRCC-specific death
(P¼ 0.013).
There were 19 patients with locally advanced non-metastatic
ccRCC (pT3N0M0) with a median follow-up of 90 months (IQR
42–105 months). Eight out of 10 patients (80%) with 9p-deleted
tumours died from advanced renal cancer compared with 1 out of
9 (11%) with normal 9p status (P¼ 0.009; Figure 3c). In this
subgroup of patients, 9p loss was the only significant variable on
univariate analysis (hazard ratio 10.071; P¼ 0.026).
Sixteen out of 68 patients (23.5%) with localised ccRCCs at
diagnosis developed recurrence with the median time to recurrence
being 35.5 months. 9p deletion, pT-stage, microvascular invasion
and age were associated with increased risk of recurrence on
univariate analysis in our cohort (Table 2). In the non-9p-deleted
tumours, only 11% developed recurrences at 5 and 10 years of
follow-up, in contrast to 8%, 34% and 55% of patients with
9p-deleted tumours showing recurrences at 1, 5 and 10 years,
respectively (P¼ 0.004; Figure 3b). We observed a more aggressive
pattern of recurrence in patients with 9p-deleted tumours
involving distant organs when first detected; in 11 out of 12 cases
disease recurred distantly, whereas 3 out of the 4 patients with
non-9p-deleted tumours had the first site of recurrence in the
resected renal bed (P¼ 0.026).
In multivariate analysis, 9p deletion was an independent
prognostic factor in both models for DSS (Table 3). Patients with
9p-deleted tumours had 4.6- and 4-fold higher risk of mortality
from advanced renal cancer compared with the non-deleted ones
in DSS models 1 and 2, respectively. The inclusion of 9p status in
model 1 beside T-stage and state of metastasis improved the
predictive accuracy expressed by C-index from 0.858 to 0.911
(P¼ 0.001). Adding 9p status to the SSIGN score in model 2
increased the predictive accuracy of the SSIGN score expressed by
the C-index from 0.877 to 0.931 (P¼ 0.001). In model 3, 9p
deletion was an independent predictor of recurrence (hazard ratio
3.863; P¼ 0.021) with pT-stage (Table 3).
DISCUSSION
We performed analytic validation of I-FISH in the assessment of
9p deletion in ccRCC in a cohort of patients with the longest
reported period of follow-up. We used the same probe reported in
the previous studies, and relied on normal renal tissue as a negative
control to determine the threshold level for 9p deletion with a good
level of interobserver agreement. The use of a negative control to
determine the cut-off threshold for deletion makes the scoring
method more reliable, objective and reproducible.
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Figure 2. Agreed 9p status in tumour blocks by total number of cores scored.
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It is known that intratumour heterogeneity and complexity
could be underestimated or missed as a result of sampling bias if a
small number of biopsy cores are used (Martinez et al, 2013). Also,
there is a general realisation that biomarker research using TMA
may not be sufficient to adequately represent whole-tissue
specimens (Eckel-Passow et al, 2010). The detection rate of 9p
deletion in the current study is 44%, which is higher than that
reported in the literature—ranging between 14 and 18% in studies
employing I-FISH on TMA (Brunelli et al, 2008; La Rochelle et al,
2010).
The higher detection rate of 9p deletion could be partly
explained by the difference in cut-off threshold for deletion. It
could also be explained by the use of six cores to represent the
excised tumours, in the present study, rather than three cores in
the previous studies. Our findings show a trend towards higher
detection rate of 9p deletion with increasing number of scored
cores (Figure 2). We showed a 100% concordance between whole-
tissue sections and representative cores, with at least four out of the
six cores scored, whether the tumour was 9p deleted or non-
deleted.
It is important to note that we also applied the scoring
technique suggested by La Rochelle et al (2010) using only the first
three cores from each tumour on the TMA. The detection rate of
9p loss was 18% (15 out of 80), which matches the one reported by
La Rochelle et al (2010)—14%. There was a significant difference in
DSS at 10 years of follow-up between 9p-deleted and non-9p-
deleted tumours in the same cohort of patients (20% vs 70%,
respectively, Po0.001—Supplementary Figure 1) and 9p status
based on La Rochelle’s cut-off threshold remained an independent
prognostic variable on multivariate analysis for DSS with T-stage,
state of metastasis and sarcomatoid features (hazard ratio 2.956;
P¼ 0.025).
Although homozygous deletion, hypermethylation of the
promoter region and intragenic mutation have all been reported
as mechanisms of CDKN2A inactivation in cell lines (Herman et al,
1995), they all seem to be rare events in primary renal tumours
(Cairns et al, 1995; Sanz-Casla et al, 2003). Most of the studies
looking at 9p deletion in primary renal tumours, and not in cell
lines, found LOH of 9p21 locus (CDKN2A) to be the most
commonly reported CNV (Schullerus et al, 1997; Grady et al, 2001;
Presti et al, 2002; Brunelli et al, 2008; La Rochelle et al, 2010).
In the present study, 91% (32 out of 35) of 9p deletion observed
was due to the loss of one copy of the CDKN2A (either LOH or
monosomy). Only three tumours showed deletion of both copies
(homozygous deletion). It is well known that CNV correlates with
gene expression (Knudson’s theory)—loss of one allele allows the
inactivation of the gene if the remaining copy is mutated or it could
result in lower expression of the tumour suppressor protein.
Aberrations, leading to low expression of p16INK4A and p14ARF,
have been associated with aggressive ccRCC and poorer prognosis
(Kawada et al, 2001b; Ikuerowo et al, 2007).
The principal findings of the present study are that ccRCC with
9p loss is associated with higher stage and larger size tumours, and
Table 1. Clinicopathological parameters by 9p deletion status
Clear cell RCC Number of cases (n) (%)
Variables
9p deleted
Non-9p
deleted P-value
Total n 35 (44%) 45 (56%)
Age at diagnosis (years; mean (s.d.)) 65.94 (10.7) 60.4 (11.92) 0.043a
Tumour size (cm, mean (s.d.)) 7.7 (3.42) 5.6 (2.54) 0.002a
Gender
Male 24 (69%) 26 (58%) 0.360
Female 11 (31%) 19 (42%)
T stage
pT1a 3 (9%) 15 (33%) 0.021a
pT1b 7 (20%) 11 (24%)
pT2a 6 (17%) 5 (11%)
pT2b 2 (6%) 1 (2%)
pT3a 12 (34%) 13 (29%)
XpT3b 5 (14%) 0
N stage
N0/x 32 (91%) 45 (100%) 0.080
N1/2 3 (9%) 0
M stage
M0 29 (82%) 41 (91%) 0.320
M1 6 (18%) 4 (9%)
Metastasis
N0M0 27 (77%) 41 (91%) 0.166
NþMþ 8 (23%) 4 (9%)
Fuhrman grade
G1/G2 11 (31%) 20 (44%) 0.360
G3/G4 24 (69%) 25 (56%)
Tumour necrosis
Present 18 (51%) 11 (24%) 0.019a
Absent 17 (49%) 34 (76%)
SSIGN score
0–2 7 (20%) 23 (51%) 0.033a
3-4 5 (14%) 3 (7%)
5-6 7 (20%) 10 (22%)
7-9 10 (29%) 6 (13%)
X10 6 (17%) 3 (7%)
Sarcomatoid change
Present 3 (9%) 3 (7%) 1.0
Absent 32 (91%) 42 (93%)
Microvascular invasion
Present 16 (46%) 10 (22%) 0.032a
Absent 19 (54%) 35 (78%)
Renal vein invasion
Present 11 (31%) 5 (11%) 0.046a
Absent 24 (69%) 40 (89%)
Pelvicalyceal invasion
Present 6 (17%) 7 (16%) 1.000
Absent 29 (83%) 38 (84%)
Table 1. ( Continued )
Clear cell RCC Number of cases (n) (%)
Variables
9p deleted
Non-9p
deleted P-value
Renal sinus invasion
Present 10 (29%) 6 (13%) 0.102
Absent 25 (71%) 39 (87%)
Abbreviations: RCC¼ renal cell carcinoma; SSIGN¼ stage, size, grade and necrosis.
aStatistically significant
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is more likely to have adverse histopathological features (tumour
necrosis, microvascular invasion and renal vein involvement).
A statistically nonsignificant trend was observed between
9p-deleted ccRCC tumours and higher Fuhrman grade. Our
finding is in agreement with previous reports suggesting an
association between 9p deletion and ccRCC progression
(Klatte et al, 2009; La Rochelle et al, 2010; Dagher et al, 2013).
The prognostic impact of 9p deletion on ccRCC remains a
controversial matter. Several studies assessed the impact of 9p
status in ccRCC on survival using different molecular and genetic
techniques with median follow-up periods ranging between 31 and
73 months. Two studies showed that 9p deletion was not associated
with poor prognosis (Presti et al, 2002; Antonelli et al, 2010). On the
other hand, three studies concluded that 9p deletion was associated
with worse prognosis on univariate analysis only (Moch et al, 1996;
Schraml et al, 2001; Sanjmyatav et al, 2011). Whereas in two studies
9p loss remained an independent predictor of outcome in ccRCC on
multivariate analysis. I-FISH was the main technique employed to
assess 9p status in those two studies with different scoring
techniques and threshold levels for deletion (Brunelli et al, 2008;
La Rochelle et al, 2010). In our cohort of ccRCC, with the longest
median follow-up of 95 months, survival analysis showed that
patients with 9p-deleted tumours had a higher risk of recurrence and
cancer-specific mortality. On multivariate analysis, it appears that 9p
deletion remains a poor prognosticator for both outcomes,
confirming the findings from previous studies based on I-FISH.
Several nomograms to predict the prognosis in RCC, relying on
clinical and pathological parameters, have been developed and
some have been externally validated. The integration of molecular
or genetic biomarker, besides pathological and clinical parameters,
has been attempted to improve the prognostication of some
nomograms (Kim et al, 2005; Karakiewicz et al, 2007; Klatte et al,
2009). The addition of 9p status to prognostic models for ccRCC
improved the predictive accuracy of DSS up to 89% (Klatte et al,
2009; La Rochelle et al, 2010). In the present study, SSIGN score
and 9p status were independent predictors of outcome on
multivariate analysis, mirroring the findings by Brunelli et al
(2008). We have shown that the integration of 9p status to the well-
established, externally validated, SSIGN score improved its
predictive accuracy of DSS to 93.1%.
We acknowledge that the present study is limited by its
retrospective nature. However, we made every effort to avoid bias.
The use of preset scoring criteria, assessment of FISH score in a
blinded manner by two independent observers, data collection
using a validated electronic linkage methodology by third party,
characterisation of tumours by a single pathologist with special
interest in renal cancer, the representation of tumour by six cores
on the TMA, use of normal tissue as a negative control to define
threshold of 9p loss and systematic protocol-guided long-term
follow-up exceeding those reported in the literature are the
strengths of our study.
Lack of reporting of previous studies in a rigorous manner and
published articles often showing insufficient information have been
highlighted by reporting recommendations for a tumour marker
prognostic studies (REMARK guidelines) (McShane et al, 2006)
panel following a consensus meeting between US National Cancer
Institute and the European Organisation for Research and
Treatment of Cancer (NCI-EORTC) experts. We have adhered
to these recommendations in reporting the present study
(Supplementary Table 1).
The 9p deletion detected by I-FISH in ccRCC, regardless of the
cut-off threshold, retained its prognostic value. Therefore, we
believe that the potential use of this predictive biomarker in ccRCC
should be further explored after agreeing on scoring technique,
cut-off threshold for deletion and the number of cores required,
keeping in mind intratumour heterogeneity.
We also suggest that a consensus statement is required to
standardise I-FISH scoring for chromosomal deletion in renal
tissue as this could have an implication on translational research
in the area of renal cancer. 9p status could be used to predict
behaviour of clinically localised SRMs and help in stratifying
patients who may need interventions or surveillance. The change
in size of SRMs on serial imaging is currently used as a surrogate
marker of tumour progression in most of the centres across the
world; however, this may not be the best indicator of
aggressiveness. Our findings of worse prognosis in clinically
localised SRMs (o4 cm) (Supplementary Figure 2) corroborates
with previous reports and suggests that 9p-deleted SRMs could
have a different behaviour and hence be a reason for early
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Figure 3. Kaplan–Meier survival analysis. (A) RCC disease-specific
survival (DSS) by 9p deletion status. (B) Recurrence-free survival (RFS) in
localised RCC by 9p deletion status. (C) Disease-specific survival (DSS)
in locally advanced non-metastatic RCC (pT3N0M0) by 9p deletion
status.
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intervention. Similarly, our observation of poor survival in
9p-deleted locally advanced non-metastatic (pT3N0M0)
ccRCC, which was previously reported (Moch et al, 1996;
Schraml et al, 2001), may be used to counsel patients for
recruitment into adjuvant treatment for locally advanced
tumours. This should, ideally, be further assessed in prospective
randomised controlled trials.
CONCLUSION
Loss of 9p is associated with aggressive clear cell carcinoma of
kidney and portends a worse prognosis in patients following surgery.
Our findings independently confirm the findings of previous reports
relying on I-FISH to detect 9p (CDKN2A) deletion.
Table 3. Multivariate Cox proportional hazards analysis
95% CI
Variable Categories P-value Hazard ratio Lower Upper
Model 1 for RCC DSS
9p status Deletion vs no deletion 0.007 4.603 1.527 13.873
T-stage pT3/4 vs pT1/2 0.002 8.329 2.181 31.803
Metastasis NþMþ vs N0M0 0.007 3.707 1.437 9.563
Model 2 for RCC DSS
9p status Deletion vs no deletion 0.014 4.002 1.322 12.111
SSIGN score 5 subcategories o0.001 3.013 1.918 4.731
Model 3 for RFS
T-stage pT3/4 vs pT1/2 0.021 3.863 1.224 12.194
9p status Deletion vs no deletion 0.021 3.323 1.198 9.220
Abbreviations: CI¼ confidence interval; DSS¼disease-specific survival; RCC¼ renal cell carcinoma; RFS¼ reoccurance-free survival; SSIGN¼ stage, size, grade and necrosis. Bold is used to
highlight the statistically significant P-values.
Table 2. Univariate Cox proportional hazards analysis
95% CI
Variable Categories P-value Hazard ratio Lower Upper
Univariate analysis for RCC DSS
Age Scale 0.074 1.036 0.997 1.076
Gender Male vs female 0.758 0.867 0.035 2.149
Tumour size Scale o0.001 1.319 1.170 1.488
T-stage pT3/4 vs pT1/2 o0.001 14.276 4.457 53.405
Metastasis NþMþ vs N0M0 o0.001 11.905 4.881 29.037
Necrosis Present vs absent 0.009 3.235 1.338 7.821
Pelvicalyceal invasion Present vs absent 0.015 3.281 1.255 8.574
Microvascular invasion Present vs absent o0.001 5.397 2.148 13.560
Sarcomatoid features Present vs absent 0.548 1.565 0.364 6.726
Fuhrman grade G3/4 vs G1/2 0.042 3.121 1.043 9.340
9p status Deletion vs no deletion 0.001 6.089 2.047 18.115
SSIGN score 5 Subcategories o0.001 3.207 2.022 5.068
Univariate analysis for RFS
Age Scale 0.007 1.065 1.018 1.114
Gender Male vs female 0.947 1.035 0.376 2.853
Tumour size Scale 0.107 1.167 0.967 1.409
pT-stage pT3/4 vs pT1/2 0.004 4.334 1.603 11.722
Necrosis Present vs absent 0.160 2.026 0.757 5.417
Pelvicalyceal invasion Present vs absent 0.285 1.996 0.562 7.098
Microvascular invasion Present vs absent 0.048 2.731 1.011 7.376
Sarcomatoid features Present vs absent 0.213 2.584 0.581 11.502
Fuhrman grade G3/4 vs G1/2 0.222 1.940 0.669 5.622
9p status Deletion vs no deletion 0.008 4.642 1.494 14.421
Abbreviations: CI¼ confidence interval; DSS¼disease-specific survival; RCC¼ renal cell carcinoma; RFS¼ reoccurance-free survival; SSIGN¼ stage, size, grade and necrosis. Bold is used to
highlight the statistically significant P-values.
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